SEC investigating Illumina over acquisition of cancer test developer Grail

  • 📰 CNBC
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 72%

Argentina Noticias Noticias

Argentina Últimas Noticias,Argentina Titulares

Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

Last month, the SEC informed Illumina about the probe and requested documents and communications related to the. The agency also asked for statements and disclosures about the "conduct and compensation" of certain members of both Illumina and Grail's management, according to the filing.

Illumina's Grail deal has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 12. in AR
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

Argentina Últimas Noticias, Argentina Titulares